替普瑞酮联合西尼必利对慢性萎缩性胃炎的疗效及胃肠激素的影响

Efficacy of Teprenone Combined with Cinitapride in the Treatment of Chronic Atrophic Gastritis and Its Effect on the Gastrointestinal Hormones

目的探讨替普瑞酮联合西尼必利治疗慢性萎缩性胃炎的临床疗效,以及对患者胃肠激素和炎性因子水平的影响。方法选取医院2019年10月至2021年9月收治的慢性萎缩性胃炎患者92例,按随机数字表法分为观察组和对照组,各46例。两组患者均予基础治疗和西尼必利,观察组患者加用替普瑞酮,均治疗6周。结果观察组总有效率为91.30%,显著高于对照组的73.91%(P<0.05)。治疗后,观察组患者的胃镜病理(胃黏膜萎缩、上皮化生、异型增生)评分均显著低于对照组(P<0.05);观察组患者的胃肠激素[胃泌素(GAS)、胃动素(MTL)、胃蛋白酶原Ⅱ(PGⅡ)]水平均显著低于对照组(P<0.05);观察组患者炎性因子[蛋白酶激活受体2蛋白(PAR2)、淀粉样蛋白A(SAA)、Toll样受体4(TLR-4)]水平均显著低于对照组(P<0.05)。观察组和对照组不良反应发生率相当(15.22%比10.87%,P>0.05)。结论替普瑞酮联合西尼必利治疗慢性萎缩性胃炎的临床疗效显著,能改善患者的胃镜病理状况,降低胃肠激素水平,抑制炎性因子表达,且治疗安全性良好。

Objective To investigate the clinical efficacy of teprenone combined with cinitapride in the treatment of chronic atrophic gastritis,and its effects on the levels of gastrointestinal hormones and inflammatory factors of patients.Methods A total of 92 patients with chronic atrophic gastritis admitted to the hospital from October 2019 to September 2021 were selected and divided into the observation group and the control group by the random number table method,with 46 cases in each group.The patients in the both groups were treated with basic treatment and cinitapride,on this basis,the patients in the observation group were treated with teprenone.Both groups were treated for six weeks.Results The total effective rate in the observation group was 91.30%,which was significantly higher than 73.91%in the control group(P<0.05).After treatment,the scores of gastroscopic pathology(gastric mucosal atrophy,epithelial metaplasia and dysplasia)in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the levels of gastrointestinal hormones[gastrin(GAS),motilin(MTL)and pepsinogenⅡ(PGⅡ)]in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the levels of inflammatory factors[protease-activated receptor 2(PAR2),serum amyloid A(SAA)and Toll-like receptor-4(TLR-4)]in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was similar to that in the control group(15.22%vs.10.87%,P>0.05).Conclusion Teprenone combined with cinitapride in the treatment of chronic atrophic gastritis is effective and safe,which can improve the gastroscopic pathology,decrease the gastrointestinal hormone levels and inhibit the expression of inflammatory factors of patients.